U.S. POINTER UPDATE: New results presented in November 2026 connected heart health and brain health. Compared with the self-guided program, the structured U.S. POINTER program did more to improve blood pressure, resting heart rate, cholesterol, weight and blood sugar. People whose heart and metabolic health improved the most also had the biggest gains in thinking and memory. The results held across age, sex and genetic risk. Learn more.
The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) was a two-year clinical trial that tested whether lifestyle interventions that simultaneously target many risk factors protect cognitive function in older adults who are at increased risk for cognitive decline. Follow-up research is looking at how the program affects heart health, sleep, the gut and aging, and the Alumni Extension is following participants for four more years.
U.S. POINTER was the first large-scale, randomized controlled clinical trial to demonstrate that an accessible healthy lifestyle program combining physical activity, nutrition, health monitoring, and cognitive exercise and social activity could protect cognitive function in diverse populations in communities across the United States.
Read about U.S. POINTER study leadership and our principal investigators.
Find out about the largest multidomain lifestyle intervention trial for the prevention of cognitive decline.
Learn how lifestyle interventions targeting multiple risk factors improved cognition in older adults at risk of cognitive decline.
U.S. POINTER was modeled on the Finnish FINGER trial, which in 2014 first showed that a two-year multidomain lifestyle program could protect thinking skills in older adults at risk. Both trials are part of World Wide FINGERS, a global network of aligned studies in communities across the globe.
In July 2026, LatAm-FINGERS, a sister trial funded by the Alzheimer's Association, reported in The Lancet that a structured lifestyle program improved cognition in 1,065 adults across 11 Latin American countries. Two trials on two continents reached the same answer.
©
Alzheimer's Association®.
All rights reserved. Alzheimer's Association is a not-for-profit 501(c)(3) organization.
Security and Privacy Policy | alz.org